Clinical Trials Logo

Filter by:
NCT ID: NCT05160818 Recruiting - Brain Metastases Clinical Trials

Hypofractionated Versus Single Fraction Stereotactic Adjuvant Radiotherapy to the Resection Cavity of Brain Metastases

SATURNUS
Start date: February 1, 2021
Phase: N/A
Study type: Interventional

This prospective, randomized, controlled, monocentric clinical phase III study focuses on stereotactic irradiation of resection cavities of brain metastases after surgical resection and seeks to demonstrate the superiority of fractionated irradiation schemes in terms of local control.

NCT ID: NCT05160714 Recruiting - Clinical trials for Head and Neck Cancer

Individualized Response-adaptive Radiation Dose Prescription in HNC Based on MRI

MRL-02
Start date: January 1, 2022
Phase: Phase 1
Study type: Interventional

This Phase 1 dose-finding study investigates the maximal tolerated dose for a subsequent phase 2 trial testing MR-guided individualized response-adaptive dose prescription in HNC.

NCT ID: NCT05160584 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

MoMMent
Start date: November 18, 2021
Phase:
Study type: Observational

The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety of current standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.

NCT ID: NCT05160272 Recruiting - Type2 Diabetes Clinical Trials

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients With Type 2 Diabetes

Start date: January 7, 2022
Phase: Phase 2
Study type: Interventional

The aim of this single-center, prospective, randomized, double-blind, placebo-controlled, 2-arm parallel-group interventional study is to investigate the effect of 4-week treatment with AP-325 on C-peptide release as measure of insulin secretion compared to placebo in type 2 diabetes (T2D) patients.

NCT ID: NCT05159752 Recruiting - Clinical trials for Xeroderma Pigmentosum

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

Start date: October 19, 2021
Phase: Phase 2
Study type: Interventional

The CUV156 study will evaluate the safety of afamelanotide in XP-C patients, as well as the drug's ability to assist reparative processes following ultraviolet (UV) provoked DNA damage of the skin. It will assess whether SCENESSE® increases the amount of UV light needed to cause DNA damage of skin cells, as well as the extent of skin repair before and after treatment.

NCT ID: NCT05158725 Recruiting - Adenoma Colon Clinical Trials

Comparison of Colonoscopy Adenoma Detection Yield

Start date: November 8, 2021
Phase: N/A
Study type: Interventional

A Prospective Randomized Comparison of colonoscopy Adenoma Detection Yield of (i) Standard Colonoscopy (SC), (ii) artificial intelligence (Discovery) aided colonoscopy, and (iii) artificial intelligence (Discovery) and permanently mounted balloon (G-EYE®) aided colonoscopy.

NCT ID: NCT05158699 Recruiting - Cataract Clinical Trials

Effectiveness of Periocular Drug Injection in CATaract Surgery

EPICAT
Start date: October 13, 2021
Phase: Phase 3
Study type: Interventional

Cystoid macular edema (CME) is a major cause of suboptimal postoperative visual acuity after cataract surgery. Topical steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs) are used to prevent CME. However, noncompliance with eye drops may compromise the effectiveness of treatment. Dropless periocular drug delivery during cataract surgery may improve the outcomes and cost-effectiveness of cataract surgery, and may alleviate the burden on homecare organizations.

NCT ID: NCT05158387 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

TITANIA
Start date: February 7, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior to enrolment.

NCT ID: NCT05157750 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Endoscopic Remission, Histologic Remission and Barrier Healing for Predicting Disease Behaviour in IBD

ERIca
Start date: January 16, 2017
Phase:
Study type: Observational

Within this study, the investigators aim to directly compare the value of endoscopic remission, histologic remission and barrier healing for predicting long-term disease behavior in a large cohort of clinically remittent IBD patients.

NCT ID: NCT05156983 Recruiting - Clinical trials for Coagulation Disorder

A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Start date: August 24, 2022
Phase: Phase 3
Study type: Interventional

The aim of this study is to find out the effects of TAK-330 compared with four-factor prothrombin complex concentrate (4F-PCC) as part of standard treatment other than Prothromplex Total for anticoagulation reversal in participants treated with Factor Xa inhibitors who require urgent surgery/invasive procedure. The participant will be assigned by chance to either TAK-330 or SOC 4F-PCC as part of standard treatment before surgery. Patients participating in this study will need to be hospitalized. They will also be contacted (via telehealth/phone call) 30 days after the surgery.